Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ultragenyx Lays Off Staff, Ends Wilson Disease Gene Therapy Program

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

Ultragenyx Pharmaceutical is laying off about 20 percent of its workforce and terminating its Wilson disease gene therapy program to focus resources on launching recently approved gene therapies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must reconsider your Wilson disease therapy plans as Ultragenyx exits this space and frees up patient and partner demand. This creates a gap for you to develop or advance alternative gene therapies faster.

◆ Coverage

1 source · 4 Nov 2026

◆ Related on Wire

◆ Topics

Biotechlayoffsgene-therapyprogram-terminationbiotechus-market